Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
108.07
-0.19 (-0.18%)
At close: May 30, 2025, 4:00 PM
108.25
+0.18 (0.17%)
After-hours: May 30, 2025, 5:23 PM EDT
Jazz Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 13 professional analysts, the 12-month price target for Jazz Pharmaceuticals stock ranges from a low of $147 to a high of $230. The average analyst price target of $181.85 forecasts a 68.27% increase in the stock price over the next year.
Price Target: $181.85 (+68.27%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Jazz Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 7 | 5 | 5 |
| Buy | 6 | 6 | 6 | 7 | 7 | 7 |
| Hold | 3 | 3 | 3 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 15 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $167 → $155 | Buy | Maintains | $167 → $155 | +43.43% | May 7, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $182 → $172 | Buy | Maintains | $182 → $172 | +59.16% | May 7, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $176 → $147 | Buy | Reiterates | $176 → $147 | +36.02% | May 7, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $183 → $166 | Buy | Maintains | $183 → $166 | +53.60% | May 7, 2025 |
| Needham | Needham | Strong Buy Reiterates $200 | Strong Buy | Reiterates | $200 | +85.07% | May 7, 2025 |
Financial Forecast
Revenue This Year
4.31B
from 4.07B
Increased by 5.92%
Revenue Next Year
4.49B
from 4.31B
Increased by 4.22%
EPS This Year
5.11
from 8.65
Decreased by -40.94%
EPS Next Year
21.89
from 5.11
Increased by 328.51%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.6B | 5.0B | 5.4B | ||
| Avg | 4.3B | 4.5B | 4.8B | ||
| Low | 4.0B | 3.8B | 3.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.5% | 15.4% | 20.6% | ||
| Avg | 5.9% | 4.2% | 6.5% | ||
| Low | -2.8% | -12.1% | -12.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.09 | 26.34 | 29.41 | ||
| Avg | 5.11 | 21.89 | 24.00 | ||
| Low | 4.10 | 15.46 | 13.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -29.6% | 415.7% | 34.4% | ||
| Avg | -40.9% | 328.5% | 9.7% | ||
| Low | -52.6% | 202.7% | -38.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.